• Danya Reich
  • Corinna Eleni Psomadakis
  • Bobby Buka


A 29-year-old male presented to Primary Care with a painless vesicular rash whose distribution corresponded with the dermatome supplied by the ophthalmic branch of the trigeminal nerve. The rash was determined to be caused by reactivation of the varicella zoster virus, also known as the chickenpox virus. Reactivation of varicella zoster virus, commonly referred to as shingles, causes a unilateral and usually painful vesicular rash isolated to a single dermatome. The rash is sometimes preceded by tingling, burning, or aching sensations. Ideally the condition is treated within the first 72 h of symptom onset with the antiviral valacyclovir. Lesions tend to resolve within 2 weeks after treatment is initiated; however, a minority of patients develop postherpetic neuralgia.


Herpes Zoster Shingles Varicella zoster virus Trigeminal nerve Vesicles Vesicular rash Dermatome Valacyclovir Acyclovir Postherpetic neuralgia 


  1. 1.
    Schmader KE, Oxman MN. Chapter 194. Varicella and herpes zoster. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. p. 2382–401.Google Scholar
  2. 2.
    Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Yawn B, Saddier P, Wollan P, St Sauver J, Kurland M, Sy L. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic Proceedings [serial on the Internet]. (2007, Nov), [cited January 25, 2015]; 82(11):1341–1349. Available from: MEDLINE with Full Text.Google Scholar
  4. 4.
    Thomas SL, Wheeler JG, Hall AJ. Case-control study of the effect of mechanical trauma on the risk of herpes zoster. BMJ. 2004;328(7437):439.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66(9):1723–30.PubMedGoogle Scholar
  6. 6.
    Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.PubMedGoogle Scholar
  7. 7.
    Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2, CD006866.Google Scholar
  8. 8.
    Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2012;10, CD008858.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • Danya Reich
    • 1
  • Corinna Eleni Psomadakis
    • 2
  • Bobby Buka
    • 3
  1. 1.Department of Family MedicineMount Sinai School of Medicine Attending Mount Sinai Doctors/Beth Israel Medical Group-WilliamsburgBrooklynUSA
  2. 2.School of Medicine Imperial College LondonLondonUK
  3. 3.Department of DermatologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations